Metabonomics-based omics study and atherosclerosis
© Wu et al; licensee BioMed Central Ltd. 2011
Received: 3 October 2010
Accepted: 31 October 2011
Published: 31 October 2011
Atherosclerosis results from dyslipidemia and systemic inflammation, associated with the strong metabolism and interaction between diet and disease. Strategies based on the global profiling of metabolism would be important to define the mechanisms involved in pathological alterations. Metabonomics is the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification. Metabonomics has been used in combination with proteomics and transcriptomics as the part of a systems biology description to understand the genome interaction with the development of atherosclerosis. The present review describes the application of metabonomics to explore the potential role of metabolic disturbances and inflammation in the initiation and development of atherosclerosis. Metabonomics-based omics study offers a new potential for biomarker discovery by disentangling the impacts of diet, environment and lifestyle.
Living systems are dynamic and complex, and their behavior may be hard to predict from the properties of individual parts. Systems biology is the strategy of integrating complex data about the interactions in systems of biological components from diverse experimental sources using interdisciplinary tools and personnel . Atherosclerosis is one of the leading causes responsible for cardiovascular morbidity and mortality, a complicated and multifactorial disease associated with genotypes and environmental factors [2, 3]. It has been suggested that lipid and inflammatory component play an important role in the pathogenesis of atherosclerosis. Metabonomics is the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification . It is expected that metabonomics will become a more and more important global systems biology tool. Recently metabonomics has been used in conjunction with proteomics and transcriptomics as part of a systems biology description of cardiovascular disease. It utilizes high-throughput approaches to profile large numbers of patients as part of epidemiology studies to understand how the genome interacts with the development of atherosclerosis . Various metabolites have been identified as indicators for a variety of diseases [6, 7]. The concentrations of metabolites often vary in response to therapy or disease stage. Furthermore, the metabolites could be used as biomarkers to carry information about the sites and mechanisms of disease. Metabolites have also been used as predictive model for disease risk, individual susceptibility, or as markers of recovery from an illness .
Metabolomics requires the employment of efficient analytical tools simultaneously together with bioinformatics. Nevertheless, there is not a single analytical platform nowadays capable of analyzing the full set of metabolites in a biological sample. Metabonomics, and the related field of metabolomics, uses tools such as liquid chromatography-mass spectrometry (LC-MS) or gas chromatography-mass spectrometer (GC-MS)or capillary electrophoresis and nuclear magnetic resonance (NMR) spectroscopy to analyze chemical components . Jeremy K. Nicholson and John C. Lindon  said that the distinction between metabonomics and metabolomics is mainly philosophical, rather than technical. The basic principle of relating chemical patterns to biology is same. In practice, the two terms are often used interchangeably. Metabolic disturbances are the key factor in both the initiation and progression of atherosclerosis. There is ample evidence that hypercholesterolemia (that is, elevated plasma levels of low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) induced by genetic modification or enhanced intake of dietary lipids is a major causative factor in atherogenesis [11, 12]. Because samples of biological fluids (usually urine or blood) can be collected fairly easily, the time-dependent fluctuations of metabolites that occur in response to disease, drug effects or other stimuli. By using GC-MS or NMR, metabonomics can easily study these changes in real-time way. And metabonomics cuts through the problems by monitoring the global outcome of all the influential factors for example environmental and lifestyle factor, without making assumptions about the effect of any single contribution to that outcome.
Moreover, to compare with proteomics and transcriptomics, metabonomics is rather rapid and economic . Metabonomics is also a high throughput approach used in a large scale of population epidemic study, while transcriptomic studies can be quite costly and proteomic studies relatively time consuming .
Data handling of metabonomics in atherosclerosis study
Multiple analytical techniques and metabolome database are developed in recent years. Spectral processing and post-experimental data analysis are the major tasks in metabonomics studies. While in data analysis, the Principal Components Analysis (PCA), Hierarchical Cluster Analysis (HCA), Soft Independent Modeling of Class Analogy (SIMCA) and Artificial Neural Network (ANN) are the major techniques. The researchers could select them according to the research destination . The data generated in metabonomics usually consist of measurements performed on subjects under various conditions. Several statistical programs are currently available for analysis of both NMR and mass spectrometry data. The first comprehensive software was developed by the Siuzdak laboratory at The Scripps Research Institute in 2006. It is called XCMS, is freely available, has over 20,000 downloads since its inception in 2006 , and is one of the most widely cited mass spectrometry-based metabolomics software programs in scientific literature. Other popular metabolomics programs [16–18] for mass spectral analysis are MZmine, MetAlign, MathDAMP, which also compensate for retention time deviation during sample analysis. Although a high-throughput metabolomics approach to atherosclerosis studies brings many advantages, it also brings a danger of generating false-positive associations due to multiple testing and overfitting of data. Application of traditional statistical approaches (e.g., Bonferroni correction) in this setting tends to levy an insurmountable statistical penalty that can obscure biologically relevant associations. Even newer statistical techniques [19, 20], such as advanced resampling methods or control of the false discovery rate, do not adequately address the fundamental problem of how to detect subtle but important changes in multiple variables identified in an "omics" approach.
Meanwhile, there are more and more database, e.g., Small Molecule Pathway Database (SMPDB), LIPID Metabolites And Pathways Strategy (LIPID MAPS), Human Metabolome Database (HMDB) to support metabolomics study [21, 22]. HMDB  is a Web-based bioinformatic/cheminformatic resource with detailed information about human metabolites and metabolic enzymes. It could be used for fields of study including metabolomics, biochemistry, clinical chemistry, biomarker discovery, medicine, nutrition, and general education. Since its first release in 2007, the HMDB has been used to facilitate the research for nearly 100 published studies in metabolomics, clinical biochemistry and systems biology.
Metabonomic strategies to study metabolic disturbances and lipotoxicity
Metabolic disturbance of atherosclerosis exist not only in circulation, but also could be found in local vessel. Using 2-dimensional gel electrophoresis and mass spectrometry, researchers identified 79 protein species that were altered during various stages of atherogenesis . Simultaneously by using NMR, they found a decline in alanine and a depletion of the adenosine nucleotide pool in vessels of 10-week-old apolipoprotein E-knockout mice . More importantly, the study demonstrated the power of a combined "-omics" platform. These techniques complemented each other and provided a more comprehensive dataset of protein and metabolite changes during atherogenesis and highlights potential associations of immune-inflammatory responses, oxidative stress, and energy metabolism. The study suggested that vascular cells might respond to hyperlipidemia by metabolizing lipids instead of glucose. Increased fatty acid oxidation would exert a negative feedback on the activity of the pyruvate dehydrogenase complex slowing down glucose metabolism, the main source of energy for the vasculature [29, 30]. For further elucidation, the researchers observe the effects of attenuating lesion formation. They found it was associated with alterations of reduced form of nicotinamide-adenine dinucleotide phosphate (NADPH) generating malic enzyme, which provides reducing equivalents for lipid synthesis and glutathione recycling, and successful replenishment of the vascular energy pool .
Metabonomics also offers a deep insight on the clinical study of atherosclerosis related disease. The plasma of patients with stable carotid atherosclerosis have been fingerprinted with both GC-MS and 1HNMR . 24 metabolites that were significantly modified in the group of atherosclerotic patients and were associated to alterations of the metabolism characteristics of insulin resistance that can be strongly related to the metabolic syndrome. For example, D-glucose, 3-OH-butyrate (3HB) and acetoacetate were increased; citrate, isocitrate, succinate and malate were downregulated. The correlations among the results of GC-MS and 1H NMR fingerprints can provide complementary information and a deeper insight into the patient state. However, clinical investigation is few, while most studies have focused on the pathophysiological study of atherosclerosis on the animal models. Given the current interest in this field, particularly in drug efficacy assessment and lifestyle and diet interventions, there is urgent needs to enhance clinical metabonomics study .
Metabonomic strategies to study inflammation in atherosclerosis
More and more studies in basic and experimental science have illuminated the role of inflammation and the underlying cellular and molecular mechanisms that contribute to atherogenesis. The development of atherosclerosis-induced metabolic perturbations of fatty acids, such as palmitate, stearate, and 1-monolinoleoylglycerol, showed that palmitate significantly contributes to atherosclerosis development via targeting apoptosis and inflammation pathways . Metabolic disturbances in the vasculature stimulate local secretion of inflammatory cytokines. Recent studies implied that the metabolic actions of cytokines such as Interleukin-6 may aim to maintain glucose homeostasis in the smooth muscle cells and contribute to the general adaptation of the vasculature to stress stimuli .
Metabonomics study has also been used to assess anti-inflammatory drug efficiency in atherosclerotic cardiovascular disease such as myocardial infarction (MI). Using metabolomic profiling of the inflammatory lipid mediators, Li N and colleagues [35, 36] documented a significant decrease in epoxyeicosatrienoic acids/dihydroxyeicosatrienoic acids ratio in MI model, which predicted a heightened inflammatory state. Treatment with soluble epoxide hydrolase (sEH) inhibitors caused altered pattern of lipid mediators from inflammation towards resolution. Meanwhile, the oxylipin profiling showed a significant parallel to the changes of inflammatory cytokines in the model. Although few studies are available, metabolomics techniques provide evidence for new therapeutic potentials of cardiovascular disease.
As the field of metabonomics advances, the ways in which metabolites affect atherosclerotic states will become clearer, and prevention and treatment of this process will become more focused. The integration of metabonomics with genetics, proteomics, and transcriptomics would provide a systems biology description of atherosclerotic cardiovascular diseases. A major challenge in the future will be the bioinformatics side of metabonomics. For systems biology, the integration of multi-level Omics profiles (also across species) is considered as central element [37, 38]. Traditional statistical methods for the study of static Omics datasets are of limited relevance and new methods are required.
This work was supported by grants from National Nature Science Foundation of China (NSF30670911), the programs of Science and Technology Commission of Shanghai Municipality (03JC14085, 08PJ1402900, 08DZ2293104, 074119634, 09DZ2260300,08410701300 and 09540702600), Key Projects in the National Science & Technology Pillar Program in the Eleventh Five-year Plan Period (2008BAI60B04), Fudan University and Zhongshan Hospital Grant for Distinguished Professor, and Shanghai Leading Academic Discipline Project (T0206, B115).
- Kitano H: Systems biology: a brief overview. Science. 2002, 295: 1662-1664. 10.1126/science.1069492.View ArticlePubMedGoogle Scholar
- Ambrose JA, Srikanth S: Vulnerable plaques and patients: improving prediction of future coronary events. American Journal of Medicine. 2010, 123: 10-16. 10.1016/j.amjmed.2009.07.019.View ArticlePubMedGoogle Scholar
- Naghavi M, Libby P, Falk E: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003, 108: 1772-1778. 10.1161/01.CIR.0000087481.55887.C9.View ArticlePubMedGoogle Scholar
- Nicholson JK: Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol. 2006, 2: 1-6.View ArticleGoogle Scholar
- Lewis GD, Asnani A, Gerszten RE: Application of metabolomics to cardiovascular biomarker and pathway discovery. Journal of the American College of Cardiology. 2008, 52: 117-123. 10.1016/j.jacc.2008.03.043.PubMed CentralView ArticlePubMedGoogle Scholar
- Mimmi MC, Picotti P, Corazza A, Betto E: High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry. Clin Chem Lab Med. 2011, 49: 317-324. 10.1515/CCLM.2011.060.View ArticlePubMedGoogle Scholar
- Patterson AD, Bonzo JA, Li F, Krausz KW, Eichler GS, Aslam S: Metabolomics Reveals Attenuation of the SLC6A20 Kidney Transporter in Nonhuman Primate and Mouse Models of Type 2 Diabetes Mellitus. J Biol Chem. 2011, 286: 19511-19522. 10.1074/jbc.M111.221739.PubMed CentralView ArticlePubMedGoogle Scholar
- Cavill R, Keun HC, Holmes E, Lindon JC, Nicholson JK, Ebbels TM: Genetic algorithms for simultaneous variable and sample selection in metabonomics. Bioinformatics. 2008, 25: 112-118.View ArticlePubMedGoogle Scholar
- Yang J, Song SL, Castro-Perez J, Plumb RS, Xu GW: Metabonomics and its Applications. Sheng Wu Gong Cheng Xue Bao. 2005, 21: 1-5.PubMedGoogle Scholar
- Nicholson JK, Lindon JC: Systems biology metabonomics. Nature. 2008, 455: 1054-1056. 10.1038/4551054a.View ArticlePubMedGoogle Scholar
- Chen CL, Liu IH, Fliesler SJ, Han X, Huang SS, Huang JS: Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. Journal of Cell Science. 2007, 120: 3509-3521. 10.1242/jcs.006916.PubMed CentralView ArticlePubMedGoogle Scholar
- Fessler MB, Rudel LL, Brown JM: Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Current Opinion in Lipidology. 2009, 20: 379-385. 10.1097/MOL.0b013e32832fa5c4.PubMed CentralView ArticlePubMedGoogle Scholar
- Lindon John, Nicholson Jeremy, Holmes Elaine: The handbook of metabonomics and metabolomics 2006. Elsevier ScienceGoogle Scholar
- Dieterle F, Riefke B, Schlotterbeck G, Ross A, Senn H, Amberg A: NMR and MS methods for metabonomics. Methods Mol Biol. 2011, 691: 385-415. 10.1007/978-1-60761-849-2_24.View ArticlePubMedGoogle Scholar
- Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G: XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem. 2006, 78: 779-787. 10.1021/ac051437y.View ArticlePubMedGoogle Scholar
- Katajamaa M, Miettinen J, Oresic M: MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics. 2006, 22: 634-636. 10.1093/bioinformatics/btk039.View ArticlePubMedGoogle Scholar
- Lommen A: MetAlign: interface-driven, versatile metabolomics tool for hyphenated full-scan mass spectrometry data processing. Anal Chem. 2009, 81: 3079-3086. 10.1021/ac900036d.View ArticlePubMedGoogle Scholar
- Baran R, Kochi H, Saito N, Suematsu M, Soga T, Nishioka T, Robert M, Tomita M: MathDAMP: a package for differential analysis of metabolite profiles. BMC Bioinformatics. 2006, 7: 530-10.1186/1471-2105-7-530.PubMed CentralView ArticlePubMedGoogle Scholar
- Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003, 100: 9440-9445. 10.1073/pnas.1530509100.PubMed CentralView ArticlePubMedGoogle Scholar
- Trygg J, Holmes E, Lundstedt T: Chemometrics in metabonomics. J Proteome Res. 2007, 6: 469-479. 10.1021/pr060594q.View ArticlePubMedGoogle Scholar
- Frolkis A, Knox C, Lim E: SMPDB: The Small Molecule Pathway Database. Nucleic Acids Research. 2010, 38: D480-487. 10.1093/nar/gkp1002.PubMed CentralView ArticlePubMedGoogle Scholar
- Wishart DS, Knox C, Guo AC: HMDB: a knowledgebase for the human metabolome. Nucleic Acids Research. 2009, 37: D603-610. 10.1093/nar/gkn810.PubMed CentralView ArticlePubMedGoogle Scholar
- Wishart DS: Human Metabolome Database: completing the 'human parts list'. Pharmacogenomics. 2007, 8: 683-686. 10.2217/14622418.104.22.1683.View ArticlePubMedGoogle Scholar
- Watson AD: Lipidomics: a global approach to lipid analysis in biological systems. Journal of Lipid Research. 2006, 47: 2101-2111. 10.1194/jlr.R600022-JLR200.View ArticlePubMedGoogle Scholar
- Clish CB, Davidov E, Oresic M: Integrative biological analysis of the APOE*3-leiden transgenic mouse. OMICS. 2004, 8: 3-13. 10.1089/153623104773547453.View ArticlePubMedGoogle Scholar
- Martin JC, Canlet C, Delplanque B: 1H NMR metabonomics can differentiate the early atherogenic effect of dairy products in hyperlipidemic hamsters. Atherosclerosis. 2009, 206: 127-133. 10.1016/j.atherosclerosis.2009.01.040.View ArticlePubMedGoogle Scholar
- Zhang F, Jia Z, Gao P: Metabonomics study of atherosclerosis rats by ultra fast liquid chromatography coupled with ion trap-time of flight mass spectrometry. Talanta. 2009, 79: 836-844. 10.1016/j.talanta.2009.05.010.View ArticlePubMedGoogle Scholar
- Mayr M, Chung YL, Mayr U: Proteomic and metabolomic analyses of atherosclerotic vessels from apolipoprotein E-deficient mice reveal alterations in inflammation, oxidative stress, and energy metabolism. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005, 25: 2135-2142. 10.1161/01.ATV.0000183928.25844.f6.View ArticlePubMedGoogle Scholar
- Bryson JM, Cooney GJ, Wensley VR, Phuyal JL, Caterson ID: The effects of the inhibition of fatty acid oxidation on pyruvate dehydrogenase complex activity in tissues of lean and obese mice. International journal of obesity and related metabolic disorders. 1996, 20: 738-744.PubMedGoogle Scholar
- Lynch RM, Paul RJ: Compartmentation of glycolytic and glycogenolytic metabolism in vascular smooth muscle. Science. 1983, 222: 1344-1346. 10.1126/science.6658455.View ArticlePubMedGoogle Scholar
- Teul J, Rupérez FJ, Garcia A: Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. Journal of Proteome Research. 2009, 8: 5580-55896. 10.1021/pr900668v.View ArticlePubMedGoogle Scholar
- Chen X, Liu L, Palacios G, Gao J, Zhang N, Li G, Lu J, Song T, Zhang Y, Lv H: Plasma metabolomics reveals biomarkers of the atherosclerosis. Sep Sci. 2010, 33: 2776-2783. 10.1002/jssc.201000395.View ArticleGoogle Scholar
- Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK: Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004, 53: 1643-1648. 10.2337/diabetes.53.7.1643.View ArticlePubMedGoogle Scholar
- Kleemann R, Verschuren L, van Erk MJ: Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biology. 2007, 8: R200-10.1186/gb-2007-8-9-r200.PubMed CentralView ArticlePubMedGoogle Scholar
- Li N, Liu JY, Timofeyev V: Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches. Journal of Molecular and Cellular Cardiology. 2009, 47: 835-845. 10.1016/j.yjmcc.2009.08.017.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu JY, Yang J, Inceoglu B: Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochemical Pharmacology. 2010, 79: 880-887. 10.1016/j.bcp.2009.10.025.PubMed CentralView ArticlePubMedGoogle Scholar
- Buschow SI, Lasonder E, van Deutekom HW: Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level. Journal of Proteome Research. 2010, 9: 1727-1737. 10.1021/pr9008546.View ArticlePubMedGoogle Scholar
- Nibbe RK, Koyutürk M, Chance MR: An integrative-omics approach to identify functional sub-networks in human colorectal cancer. PLoS Computational Biology. 2010, 6: e1000639-10.1371/journal.pcbi.1000639.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.